Tanya M Laidlaw1, Joshua M Levy2. 1. Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. tlaidlaw@partners.org. 2. Department of Otolaryngology - Head and Neck Surgery, Emory University School of Medicine, Atlanta, GA, USA.
Abstract
PURPOSE OF REVIEW: This review summarizes the latest information on the appropriate identification, evaluation, and treatment of patients with nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NSAID-ERD), also known as aspirin-exacerbated respiratory disease (AERD). Within the framework of our understanding of the underlying pathophysiology of NSAID-ERD, we also provide an update regarding new surgical techniques and newly available or upcoming medical therapies that may benefit these patients. RECENT FINDINGS: There have been considerable developments regarding recommendations for both the extent and timing of sinus surgery for NSAID-ERD. The last few years have also given us several new biologic medications that warrant consideration in the treatment of patients with recalcitrant NSAID-ERD. Further clinical trials are underway to investigate additional medications that may decrease the type 2 inflammation that dominates this disease. Despite the severe lower respiratory inflammation and recurrent nature of the nasal polyps in patients with NSAID-ERD, significant recent advances now afford much-improved quality of life for these patients. Careful collaboration between Allergy/Immunology and Rhinology specialists is imperative to ensure proper treatment of patients with NSAID-ERD.
PURPOSE OF REVIEW: This review summarizes the latest information on the appropriate identification, evaluation, and treatment of patients with nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NSAID-ERD), also known as aspirin-exacerbated respiratory disease (AERD). Within the framework of our understanding of the underlying pathophysiology of NSAID-ERD, we also provide an update regarding new surgical techniques and newly available or upcoming medical therapies that may benefit these patients. RECENT FINDINGS: There have been considerable developments regarding recommendations for both the extent and timing of sinus surgery for NSAID-ERD. The last few years have also given us several new biologic medications that warrant consideration in the treatment of patients with recalcitrant NSAID-ERD. Further clinical trials are underway to investigate additional medications that may decrease the type 2 inflammation that dominates this disease. Despite the severe lower respiratory inflammation and recurrent nature of the nasal polyps in patients with NSAID-ERD, significant recent advances now afford much-improved quality of life for these patients. Careful collaboration between Allergy/Immunology and Rhinology specialists is imperative to ensure proper treatment of patients with NSAID-ERD.
Authors: Maciej Kupczyk; Zofia Kurmanowska; Izabela Kupryś-Lipińska; Małgorzata Bocheńska-Marciniak; Piotr Kuna Journal: Respir Med Date: 2010-05-10 Impact factor: 3.415
Authors: Henry P Barham; Vijay R Ramakrishnan; Anna Knisely; Timothy Quy-Phong Do; Lyndon S Chan; Dakshika A Gunaratne; Jared D Weston; Sheran Seneviratne; George N Marcells; Raymond Sacks; Richard J Harvey Journal: Int Forum Allergy Rhinol Date: 2016-01-11 Impact factor: 3.858
Authors: Richard R Orlandi; Todd T Kingdom; Peter H Hwang; Timothy L Smith; Jeremiah A Alt; Fuad M Baroody; Pete S Batra; Manuel Bernal-Sprekelsen; Neil Bhattacharyya; Rakesh K Chandra; Alexander Chiu; Martin J Citardi; Noam A Cohen; John DelGaudio; Martin Desrosiers; Hun-Jong Dhong; Richard Douglas; Berrylin Ferguson; Wytske J Fokkens; Christos Georgalas; Andrew Goldberg; Jan Gosepath; Daniel L Hamilos; Joseph K Han; Richard Harvey; Peter Hellings; Claire Hopkins; Roger Jankowski; Amin R Javer; Robert Kern; Stilianos Kountakis; Marek L Kowalski; Andrew Lane; Donald C Lanza; Richard Lebowitz; Heung-Man Lee; Sandra Y Lin; Valerie Lund; Amber Luong; Wolf Mann; Bradley F Marple; Kevin C McMains; Ralph Metson; Robert Naclerio; Jayakar V Nayak; Nobuyoshi Otori; James N Palmer; Sanjay R Parikh; Desiderio Passali; Anju Peters; Jay Piccirillo; David M Poetker; Alkis J Psaltis; Hassan H Ramadan; Vijay R Ramakrishnan; Herbert Riechelmann; Hwan-Jung Roh; Luke Rudmik; Raymond Sacks; Rodney J Schlosser; Brent A Senior; Raj Sindwani; James A Stankiewicz; Michael Stewart; Bruce K Tan; Elina Toskala; Richard Voegels; De Yun Wang; Erik K Weitzel; Sarah Wise; Bradford A Woodworth; Peter-John Wormald; Erin D Wright; Bing Zhou; David W Kennedy Journal: Int Forum Allergy Rhinol Date: 2016-02 Impact factor: 3.858
Authors: Jacqueline J Eastman; Kellen J Cavagnero; Adam S Deconde; Alex S Kim; Maya R Karta; David H Broide; Bruce L Zuraw; Andrew A White; Sandra C Christiansen; Taylor A Doherty Journal: J Allergy Clin Immunol Date: 2017-03-06 Impact factor: 10.793
Authors: Jonathan Corren; Jane R Parnes; Liangwei Wang; May Mo; Stephanie L Roseti; Janet M Griffiths; René van der Merwe Journal: N Engl J Med Date: 2017-09-07 Impact factor: 91.245
Authors: David K Morrissey; Ahmed Bassiouni; Alkis J Psaltis; Yuresh Naidoo; Peter-John Wormald Journal: Int Forum Allergy Rhinol Date: 2016-03-14 Impact factor: 3.858